Scohia is a specialized biopharmaceutical venture that focuses on diseases related to lifestyle such as cardiovascular, metabolic, and kidney conditions. They boast a team of experienced researchers and drug development specialists with a proven track record in pharmaceutical development, bringing their expertise in compound creation, pharmacological evaluation, and clinical development to the table. With a robust and ample development pipeline, Scohia offers various products tailored to address specific medical needs.

These include SCO-272, a direct renin inhibitor, SCO-792, an enteropeptidase inhibitor, SCO-267, a GPR40 full agonist, SCO-094, a GLP-1R/GIPR dual agonist, SCO-240, an SSTR5 antagonist, SCO-006, an IP6K inhibitor, and SCO-116, an NRF2 activator. By combining their strength in the bioventure industry and extensive knowledge in the field of lifestyle diseases, Scohia is dedicated to making a positive impact on healthcare